First Time Loading...

Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 58.47 USD 2.02% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

IMCR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Immunocore Holdings Plc operates as a holding company. [ Read More ]

The intrinsic value of one IMCR stock under the Base Case scenario is 95.82 USD. Compared to the current market price of 58.47 USD, Immunocore Holdings PLC is Undervalued by 39%.

Key Points:
IMCR Intrinsic Value
Base Case
95.82 USD
Undervaluation 39%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Immunocore Holdings PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IMCR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Immunocore Holdings PLC

Provide an overview of the primary business activities
of Immunocore Holdings PLC.

What unique competitive advantages
does Immunocore Holdings PLC hold over its rivals?

What risks and challenges
does Immunocore Holdings PLC face in the near future?

Has there been any significant insider trading activity
in Immunocore Holdings PLC recently?

Summarize the latest earnings call
of Immunocore Holdings PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immunocore Holdings PLC.

Provide P/S
for Immunocore Holdings PLC.

Provide P/E
for Immunocore Holdings PLC.

Provide P/OCF
for Immunocore Holdings PLC.

Provide P/FCFE
for Immunocore Holdings PLC.

Provide P/B
for Immunocore Holdings PLC.

Provide EV/S
for Immunocore Holdings PLC.

Provide EV/GP
for Immunocore Holdings PLC.

Provide EV/EBITDA
for Immunocore Holdings PLC.

Provide EV/EBIT
for Immunocore Holdings PLC.

Provide EV/OCF
for Immunocore Holdings PLC.

Provide EV/FCFF
for Immunocore Holdings PLC.

Provide EV/IC
for Immunocore Holdings PLC.

Show me price targets
for Immunocore Holdings PLC made by professional analysts.

What are the Revenue projections
for Immunocore Holdings PLC?

How accurate were the past Revenue estimates
for Immunocore Holdings PLC?

What are the Net Income projections
for Immunocore Holdings PLC?

How accurate were the past Net Income estimates
for Immunocore Holdings PLC?

What are the EPS projections
for Immunocore Holdings PLC?

How accurate were the past EPS estimates
for Immunocore Holdings PLC?

What are the EBIT projections
for Immunocore Holdings PLC?

How accurate were the past EBIT estimates
for Immunocore Holdings PLC?

Compare the revenue forecasts
for Immunocore Holdings PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immunocore Holdings PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immunocore Holdings PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immunocore Holdings PLC compared to its peers.

Compare the P/E ratios
of Immunocore Holdings PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Immunocore Holdings PLC with its peers.

Analyze the financial leverage
of Immunocore Holdings PLC compared to its main competitors.

Show all profitability ratios
for Immunocore Holdings PLC.

Provide ROE
for Immunocore Holdings PLC.

Provide ROA
for Immunocore Holdings PLC.

Provide ROIC
for Immunocore Holdings PLC.

Provide ROCE
for Immunocore Holdings PLC.

Provide Gross Margin
for Immunocore Holdings PLC.

Provide Operating Margin
for Immunocore Holdings PLC.

Provide Net Margin
for Immunocore Holdings PLC.

Provide FCF Margin
for Immunocore Holdings PLC.

Show all solvency ratios
for Immunocore Holdings PLC.

Provide D/E Ratio
for Immunocore Holdings PLC.

Provide D/A Ratio
for Immunocore Holdings PLC.

Provide Interest Coverage Ratio
for Immunocore Holdings PLC.

Provide Altman Z-Score Ratio
for Immunocore Holdings PLC.

Provide Quick Ratio
for Immunocore Holdings PLC.

Provide Current Ratio
for Immunocore Holdings PLC.

Provide Cash Ratio
for Immunocore Holdings PLC.

What is the historical Revenue growth
over the last 5 years for Immunocore Holdings PLC?

What is the historical Net Income growth
over the last 5 years for Immunocore Holdings PLC?

What is the current Free Cash Flow
of Immunocore Holdings PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immunocore Holdings PLC.

Financials

Balance Sheet Decomposition
Immunocore Holdings PLC

Current Assets 528.8m
Cash & Short-Term Investments 442.6m
Receivables 52.1m
Other Current Assets 34.1m
Non-Current Assets 68.2m
Long-Term Investments 14.5m
PP&E 42.7m
Other Non-Current Assets 11m
Current Liabilities 139m
Accounts Payable 17.8m
Accrued Liabilities 121.2m
Non-Current Liabilities 89.1m
Long-Term Debt 48m
Other Non-Current Liabilities 41.1m
Efficiency

Earnings Waterfall
Immunocore Holdings PLC

Revenue
249.4m GBP
Cost of Revenue
-1m GBP
Gross Profit
248.4m GBP
Operating Expenses
-308m GBP
Operating Income
-59.6m GBP
Other Expenses
4.4m GBP
Net Income
-55.3m GBP

Free Cash Flow Analysis
Immunocore Holdings PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IMCR Profitability Score
Profitability Due Diligence

Immunocore Holdings PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROIC is Increasing
34/100
Profitability
Score

Immunocore Holdings PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

IMCR Solvency Score
Solvency Due Diligence

Immunocore Holdings PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Short-Term Solvency
Low D/E
71/100
Solvency
Score

Immunocore Holdings PLC's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMCR Price Targets Summary
Immunocore Holdings PLC

Wall Street analysts forecast IMCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMCR is 87.11 USD with a low forecast of 63.63 USD and a high forecast of 96.6 USD.

Lowest
Price Target
63.63 USD
9% Upside
Average
Price Target
87.11 USD
49% Upside
Highest
Price Target
96.6 USD
65% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IMCR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IMCR Price
Immunocore Holdings PLC

1M 1M
-6%
6M 6M
+27%
1Y 1Y
-4%
3Y 3Y
+47%
5Y 5Y
+125%
10Y 10Y
+125%
Annual Price Range
58.47
52w Low
42.85
52w High
75.36
Price Metrics
Average Annual Return 46.75%
Standard Deviation of Annual Returns 21.03%
Max Drawdown -66%
Shares Statistics
Market Capitalization 2.9B USD
Shares Outstanding 49 820 600
Percentage of Shares Shorted 10.43%

IMCR Return Decomposition
Main factors of price return

What is price return decomposition?

IMCR News

Other Videos

Company Profile

Immunocore Holdings PLC Logo
Immunocore Holdings PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

2.9B USD

Dividend Yield

0%

Description

Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

Contact

OXFORDSHIRE
Abingdon
90 Park Drive, Milton Park, Abingdon
+441235438600.0
http://www.immunocore.com/

IPO

2021-02-05

Employees

324

Officers

CEO & Director
Dr. Bahija Jallal Ph.D.
CFO & Head of Strategy
Mr. Brian R. Di Donato M.B.A.
SVP & Chief Operating Officer
Mr. John Trainer M.B.A.
SVP, Finance & Chief Accounting Officer
Mr. John Goll III
CTO and Head of Pipeline & Platform Research
Ms. Annelise Vuidepot Ph.D.
VP & Chief Information Officer
Mr. Sean D. Buckley
Show More
Head of Investor Relations
Clayton Robertson
General Counsel & Company Secretary
Ms. Lily Margaret Hepworth
Chief Compliance Officer
Ms. Elizabeth Varki Jobes Esq., J.D.
Head of Communications
Mr. Sébastien Desprez
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMCR stock?

The intrinsic value of one IMCR stock under the Base Case scenario is 95.82 USD.

Is IMCR stock undervalued or overvalued?

Compared to the current market price of 58.47 USD, Immunocore Holdings PLC is Undervalued by 39%.